Skip to main content

Combining 3D Cell Culture Chemosensitivity Results and NGS Profiles to Maximize Outcomes in Glioblastoma

High Grade Glioma (HGG) Functional Precision Medicine—A Six Webinar Series

Virtual 60-minute webinar featuring expert discussion of real world HGG patient cases.

SESSION 4 of 6


For this fourth installment of a six-webinar series, join us to hear how Dr. Odia of the Miami Cancer Institute at Baptist Health South Florida is using 3D Cell culture chemosensitivity results and NGS profiles to maximize outcomes in glioblastoma.

HGG patients have an extremely poor prognosis. Limited diagnostic tools are available to accurately predict treatment responses, leading to challenges in selecting effective therapeutic options. This interactive discussion will feature real world clinical cases, presented by Dr. Odia of the Miami Cancer Institute at Baptist Health South Florida, where a new functional precision oncology assay was used to direct therapy. There will be time for attendees to participate in interactive Q&A.

This Functional Precision Medicine Webinar Series is powered by OncoLens. On a single, secure platform, OncoLens data science, informatics and advanced collaboration tools provide a first of a kind platform for targeted treatment planning and confident clinical decision making.


FEATURED SPEAKER:

Yazmin Odia, MD, MS, FAANS

Chief of Neuro-Oncology
Miami Cancer Institute
Baptist Health South Florida

Feb 22, 2024 | 12:00 PM EST

High Grade Glioma (HGG) Functional Precision Medicine Webinar Series


Other Sessions